U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H24O7
Molecular Weight 388.4111
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VISNADINE

SMILES

CC[C@@H](C)C(=O)O[C@@H]1[C@H](OC(C)=O)C2=C3OC(=O)C=CC3=CC=C2OC1(C)C

InChI

InChIKey=GVBNSPFBYXGREE-CXWAGAITSA-N
InChI=1S/C21H24O7/c1-6-11(2)20(24)27-19-18(25-12(3)22)16-14(28-21(19,4)5)9-7-13-8-10-15(23)26-17(13)16/h7-11,18-19H,6H2,1-5H3/t11-,18-,19-/m1/s1

HIDE SMILES / InChI

Molecular Formula C21H24O7
Molecular Weight 388.4111
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Visnadine is a natural product extracted from the seeds and aerial parts of Ammi visnaga (Umbelliferae), plant widely used in Egyptian medicine since the Pharaohs times as antispastic and for the treatment of angina pectoris and other cardiovascular diseases. It has been used since a long time in western medicine for the treatment of various cardiac diseases and peripheral vasculopathies. Visnadine seems to act by inhibiting the contractile responses mediated by Ca2+ entry through L-type Ca2+ channels.Topical use of Visnadine may increase regional vascularization afecting turgidity and sensorial threshold of the area of application. A formulation for vulvar application (ReFeel® spray, IDI Integratori Dietetici Italiani S.r.l., Italy) has been developed and it contains Visnadine at high concentration (1%) with an elevate purity index (minimum 95%). Visnadine spray displayed positive effects on sexual function in women with and without FSD and it was well tolerated. Topical Visnadine may not only be part of multimodal strategies to manage clinically relevant sexual symptoms but also simply to help women to enhance their subjective impaired perception of sexual response.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ReFeel

Approved Use

Atrophy of the female external genitalia
Primary
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
single, topical
Studied dose
Route: topical
Route: single
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Effects of visnadine on rat isolated vascular smooth muscles.
1997-06
Study of the action of visnadine on general and cardiac hemodynamics.
1973-02
[Coronary treatment with visnadine].
1969-05-03
Patents

Sample Use Guides

15 days, 1 application per day, with a vaginal cream containing visnadine, prenylflavonoids and bovine colostrum.
Route of Administration: Vaginal
In Vitro Use Guide
Visnadine (< 10(-5) M) selectively inhibited the contractions induced by depolarization with 80 mM KCl or by CaCl2 in rat KCl-depolarized aorta and the spontaneous activity of the portal vein. At concentrations higher than 10(-5) M, visnadine also inhibited the contractile responses induced by noradrenaline and phorbol 12-myristate 13-acetate (PMA), being equipotent to inhibit noradrenaline-induced contractions in either Ca(2+)-containing or Ca(2+)-free medium and PMA-induced contractions.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:06:09 GMT 2025
Edited
by admin
on Mon Mar 31 18:06:09 GMT 2025
Record UNII
0RL4V0K263
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
3,4,5-TRIHYDROXY-2,2-DIMETHYL-6-CHROMANACRYLIC ACID D-LACTONE 4-ACETATE 3-(2-METHYLBUTYRATE).
Preferred Name English
VISNADINE
INCI   INN   MART.   MI   WHO-DD  
INN   INCI  
Official Name English
VISNADIN
Common Name English
VISNADINE [MART.]
Common Name English
VISNADINE [MI]
Common Name English
Visnadine [WHO-DD]
Common Name English
visnadine [INN]
Common Name English
Classification Tree Code System Code
WHO-ATC C04AX24
Created by admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
WHO-VATC QC04AX24
Created by admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
NCI_THESAURUS C29707
Created by admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
Code System Code Type Description
DRUG CENTRAL
3649
Created by admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
PRIMARY
ECHA (EC/EINECS)
207-515-1
Created by admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
PRIMARY
SMS_ID
100000079325
Created by admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
PRIMARY
ChEMBL
CHEMBL2104448
Created by admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
PRIMARY
MESH
C067604
Created by admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
PRIMARY
EPA CompTox
DTXSID301023583
Created by admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
PRIMARY
NCI_THESAURUS
C87287
Created by admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
PRIMARY
WIKIPEDIA
VISNADINE
Created by admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
PRIMARY
EVMPD
SUB00083MIG
Created by admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
PRIMARY
PUBCHEM
442151
Created by admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
PRIMARY
MERCK INDEX
m11478
Created by admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
PRIMARY Merck Index
INN
1832
Created by admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
PRIMARY
FDA UNII
0RL4V0K263
Created by admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
PRIMARY
CAS
477-32-7
Created by admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
PRIMARY
DRUG BANK
DB13355
Created by admin on Mon Mar 31 18:06:09 GMT 2025 , Edited by admin on Mon Mar 31 18:06:09 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> CONSTITUENT ALWAYS PRESENT
Related Record Type Details
ACTIVE MOIETY